Jaclyn M W Hughto1,2,3, Emily K Quinn4, Michael S Dunbar5, Adam J Rose6, Theresa I Shireman7,8, Guneet K Jasuja9,10,11. 1. Department of Behavioral and Social Sciences, Brown University School of Public Health, Providence, Rhode Island. 2. Center for Health Promotion and Health Equity, Brown School of Public Health, Brown University, Providence, Rhode Island. 3. Department of Epidemiology, Brown University School of Public Health, Providence, Rhode Island. 4. Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, Massachusetts. 5. RAND Corporation, Pittsburgh, Pennsylvania. 6. School of Public Health, Hebrew University, Jerusalem, Israel. 7. Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island. 8. Center for Gerontology and Healthcare Research, Brown University, Providence, Rhode Island. 9. Center for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Veterans Affairs Medical Center, Bedford, Massachusetts. 10. Department of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts. 11. OptumLabs, Eden Prairie, Minnesota.
Abstract
Importance: Substance use disorders are a major source of morbidity and mortality in the United States. National data comparing the prevalence of substance use disorder diagnoses (SUDDs) among transgender and cisgender individuals are lacking in the United States. Objectives: To investigate the prevalence of SUDDs among transgender and cisgender adults and to identify within-group and between-group differences by age, gender, and geographic location. Design, Setting, and Participants: This cross-sectional study used the OptumLabs Data Warehouse to analyze deidentified claims from approximately 74 million adults aged 18 years or older enrolled in commercial or Medicare Advantage insurance plans in 2017. A total of 15 637 transgender adults were identified based on a previously developed algorithm using a combination of International Classification of Diseases, Tenth Revision (ICD-10) transgender-related diagnosis and procedure codes and sex-discordant hormone prescriptions. A cohort of 46 911 cisgender adults was matched to the transgender cohort in a 3:1 ratio based on age and geographic location. Main Outcomes and Measures: SUDDs, based on ICD-10 codes, were assessed overall and compared between transgender and cisgender cohorts and by geographic region (ie, Northeast, Midwest, South, and West); age groups (eg, 18-25, 26-30, 31-35 years), and gender (ie, transfeminine [TF; assigned male sex at birth, identify along feminine gender spectrum], transmasculine [TM; assigned female sex at birth, identify along masculine gender spectrum], male, and female). Results: In this study of 15 637 transgender adults (4955 [31.7%] TM) and 46 911 cisgender adults (23 664 [50.4%] men), most (8627 transgender adults [55.2%]; 51 762 cisgender adults [55.2%]) were aged between 18 and 40 years, and 6482 transgender adults (41.5%) and 19 446 cisgender adults (41.5%) lived in the South. Comparing transgender to cisgender groups, significant differences were found in the prevalence of a nicotine (2594 [16.6%] vs 2551 [5.4%]; P < .001), alcohol (401 [2.6%] vs 438 [0.9%]; P < .001), and drug (678 [4.3%] vs 549 [1.2%]; P < .001) SUDDs. Among transgender adults, cannabis was the most prevalent drug SUDD (321 [2.1%]), followed by opioid SUDD (205 [1.3%]) and cocaine SUDD (81 [0.5%]), whereas among cisgender adults, cannabis and opioid SUDDs were equally prevalent (cannabis, 186 [0.4%]; opioid, 207 [0.4%]), followed by cocaine SUDD (59 [0.1%]). Conclusions and Relevance: In this study, the prevalence of SUDDs was significantly elevated among transgender adults relative to their cisgender peers. These findings underscore the need for culturally tailored clinical interventions to treat substance use disorder in transgender populations.
Importance: Substance use disorders are a major source of morbidity and mortality in the United States. National data comparing the prevalence of substance use disorder diagnoses (SUDDs) among transgender and cisgender individuals are lacking in the United States. Objectives: To investigate the prevalence of SUDDs among transgender and cisgender adults and to identify within-group and between-group differences by age, gender, and geographic location. Design, Setting, and Participants: This cross-sectional study used the OptumLabs Data Warehouse to analyze deidentified claims from approximately 74 million adults aged 18 years or older enrolled in commercial or Medicare Advantage insurance plans in 2017. A total of 15 637 transgender adults were identified based on a previously developed algorithm using a combination of International Classification of Diseases, Tenth Revision (ICD-10) transgender-related diagnosis and procedure codes and sex-discordant hormone prescriptions. A cohort of 46 911 cisgender adults was matched to the transgender cohort in a 3:1 ratio based on age and geographic location. Main Outcomes and Measures: SUDDs, based on ICD-10 codes, were assessed overall and compared between transgender and cisgender cohorts and by geographic region (ie, Northeast, Midwest, South, and West); age groups (eg, 18-25, 26-30, 31-35 years), and gender (ie, transfeminine [TF; assigned male sex at birth, identify along feminine gender spectrum], transmasculine [TM; assigned female sex at birth, identify along masculine gender spectrum], male, and female). Results: In this study of 15 637 transgender adults (4955 [31.7%] TM) and 46 911 cisgender adults (23 664 [50.4%] men), most (8627 transgender adults [55.2%]; 51 762 cisgender adults [55.2%]) were aged between 18 and 40 years, and 6482 transgender adults (41.5%) and 19 446 cisgender adults (41.5%) lived in the South. Comparing transgender to cisgender groups, significant differences were found in the prevalence of a nicotine (2594 [16.6%] vs 2551 [5.4%]; P < .001), alcohol (401 [2.6%] vs 438 [0.9%]; P < .001), and drug (678 [4.3%] vs 549 [1.2%]; P < .001) SUDDs. Among transgender adults, cannabis was the most prevalent drug SUDD (321 [2.1%]), followed by opioid SUDD (205 [1.3%]) and cocaineSUDD (81 [0.5%]), whereas among cisgender adults, cannabis and opioid SUDDs were equally prevalent (cannabis, 186 [0.4%]; opioid, 207 [0.4%]), followed by cocaineSUDD (59 [0.1%]). Conclusions and Relevance: In this study, the prevalence of SUDDs was significantly elevated among transgender adults relative to their cisgender peers. These findings underscore the need for culturally tailored clinical interventions to treat substance use disorder in transgender populations.
Authors: Sari L Reisner; Seth T Pardo; Kristi E Gamarel; Jaclyn M White Hughto; Dana J Pardee; Colton L Keo-Meier Journal: LGBT Health Date: 2015-07-29 Impact factor: 4.151
Authors: Sari L Reisner; Katie B Biello; Jaclyn M White Hughto; Lisa Kuhns; Kenneth H Mayer; Robert Garofalo; Matthew J Mimiaga Journal: JAMA Pediatr Date: 2016-05-01 Impact factor: 16.193
Authors: Pablo K Valente; Jordan D Dworkin; Curtis Dolezal; Anneliese A Singh; Allen J LeBlanc; Walter O Bockting Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2022-03-21 Impact factor: 4.328
Authors: Emily C Helminen; Cory J Cascalheira; Thomas J Shaw; Sarah Zollweg; Tonda L Hughes; Jillian R Scheer Journal: Drug Alcohol Depend Date: 2022-06-30 Impact factor: 4.852
Authors: Jaclyn M W Hughto; Landon Hughes; Kim Yee; Jae Downing; Jacqueline Ellison; Ash Alpert; Guneet Jasuja; Theresa I Shireman Journal: LGBT Health Date: 2022-03-15 Impact factor: 5.150
Authors: Michael S Dunbar; Daniel Siconolfi; Anthony Rodriguez; Rachana Seelam; Jordan P Davis; Joan S Tucker; Elizabeth J D'Amico Journal: Psychol Addict Behav Date: 2022-01-13
Authors: Landon D Hughes; Wesley M King; Kristi E Gamarel; Arline T Geronimus; Orestis A Panagiotou; Jaclyn M W Hughto Journal: Demography Date: 2022-06-01
Authors: Jaclyn M W Hughto; Arjee J Restar; Hill L Wolfe; Lily K Gordon; Sari L Reisner; Katie B Biello; Sean R Cahill; Matthew J Mimiaga Journal: Drug Alcohol Depend Date: 2021-03-18 Impact factor: 4.492
Authors: Hill L Wolfe; Katie B Biello; Sari L Reisner; Matthew J Mimiaga; Sean R Cahill; Jaclyn M W Hughto Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852